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Soluble forms of transforming growth factor-a (TGFa) are derived by proteolytic pro-
cessing of an integral membrane glycoprotein precursor (proTGFa). Previous studies
indicated that phorbol ester-induced cleavage of proTGFa in CHO cells is dependent on
the presence of a valine residue located at the carboxyl terminus of the precursor's
cytoplasmic domain. We reassessed this requirement with epitope-tagged constructs
introduced into transformed rat liver epithelial cells that normally express and process
TGFa. We found that proTGFa mutants lacking the terminal valine residues showed
greatly reduced maturation to the fully glycosylated form. Additionally, they were
present at substantially reduced levels on the cell surface and, instead, accumulated in
the endoplasmic reticulum. Consistent with these results, enzyme-linked immunosor-
bant assay (ELISA) and Western blot analyses revealed little or no soluble TGFa in
medium conditioned by cells expressing the mutant constructs. Finally, a truncated
proTGFa mutant lacking most of the cytoplasmic domain but retaining a carboxyl-
terminal valine was processed and cleaved in a near-normal manner. These results, some
of which were reproduced in CHO cells, indicate that the predominant effect of the
carboxyl-terminal valines is to ensure normal maturation and routing of the precursor.
INTRODUCTION
Polypeptide growth factors are divided into two gen-
eral categories that are distinguished by whether or
not the initial translation product is a soluble protein.
Thus, some are expressed as integral membrane
growth factors that contain receptor-binding se-
quences in their extracellular domains. Examples of
this latter category include mammalian, worm, and fly
members of the epidermal growth factor (EGF)/neu-
regulin superfamily (reviewed in Lee et al., 1995), col-
ony-stimulating factor-i (Kawasaki et al., 1985), the
c-kit ligand (KL; reviewed in Massague and Pandiella,
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ter, School of Medicine, University of North Carolina at Chapel
Hill, Chapel Hill, NC 27599-7295.
1993), ligands for the eph receptor family (Davis et al.,
1994), and Drosophila bride-of-sevenless (Boss; Hart et
al., 1990). Additionally, tumor necrosis factor-a
(TNFa) is a type II membrane glycoprotein with its
amino terminus in the cytoplasm (Kriegler et al., 1988).
Most tested members of this class are biologically
active as integral membrane proteins (Brachmann et
al., 1989; Wong et al., 1989; Perez et al., 1990; Dobashi
and Stearn, 1991; Davis et al., 1994), but many are
nevertheless cleaved to release soluble receptor li-
gands (reviewed by Ehlers and Riordan, 1991; also
Massague and Pandiella, 1993). These facts suggest an
appealing model in which the activities of membrane-
tethered growth factors are spatially regulated via
production or activation of specific proteases. Al-
though there is limited evidence to validate this
model, it is consistent with studies of the spontaneous
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mouse mutant Sld, which show that exclusive produc-
tion of a soluble bioactive KL (with complete loss of its
integral membrane precursor) yields a spectrum of
mouse phenotypes that are similar to those resulting
from loss of the KL receptor c-kit (Brannan et al., 1991).
Besides providing a mechanism for spatial regula-
tion, membrane-anchored growth factors could have
other roles as well. Because internalization of a recep-
tor complex with membrane-anchored growth factor
could be substantially slower than that of a complex
with soluble ligand, signaling consequences could be
different. For example, activation of mitogen-activated
protein kinase might be prolonged, thereby promoting
cellular differentiation instead of cellular proliferation
(Traverse et al., 1992). Integral membrane growth fac-
tors might also possess activities that are distinct from
those of their soluble derivatives. For example, bind-
ing to receptor could simultaneously enhance cell-cell
adhesion and induce the receptor's tyrosine kinase
activity, as suggested by some model studies (Ankle-
saria et al., 1990; Flanagan et al., 1991; Kaneko et al.,
1991). An especially interesting possibility is that in-
tegral membrane growth factors could participate in
bidirectional signaling and, thus, function as both re-
ceptor and ligand. This hypothesis, first put forth by
Pfeffer and Ullrich (1985), is consistent with the recent
demonstration of receptor-binding-induced tyrosine
phosphorylation of eph-receptor ligands (Holland et
al., 1996), and possibly with the identification of a
multiprotein proTGFa complex (Shum et al., 1994).
Critically important to the future evaluation of these
various possibilities is greater knowledge of the pro-
cessing proteases and their regulation. Although can-
didate activities have been described (Cappelluti et al.,
1993; Harano and Mizuno, 1994), none of the relevant
proteases have yet been cloned or characterized.
The integral membrane glycoprotein precursor to
soluble TGFa, proTGFa has emerged as a principal
model for studies of membrane-anchored growth fac-
tors and their proteolytic processing. proTGFa con-
tains 159 or 160 amino acids, depending on the use of
alternative splice acceptor sites (Derynck et al., 1984;
Lee et al., 1985; Blasband et al., 1990). Its extracellular
domain contains the mature 50-amino acid TGFa se-
quence preceded by a short sequence containing the
N-glycosylation site (O-glycosylation also occurs but
the sites have not been mapped), together with a
signal peptide. In addition to the transmembrane do-
main, it also includes a short cytoplasmic region of
approximately 40 amino acids that is rich in cysteines
and modified by palmitoylation (Bringman et al., 1987;
Shum et al., 1996). Its overall structure is distinct from
that of the much larger prepro EGF, which contains
multiple EGF-like sequences in its extracellular do-
main and also has a more extensive cytoplasmic do-
main (Gray et al., 1983; Scott et al., 1983). Although
proTGFa generally resembles precursors to the other
EGF family members, amphiregulin, heparin-binding
EGF, betacellulin, and epiregulin, these precursors
share no significant homology outside of the EGF-like
motif, and there is little similarity in the apparent
proteolytic cleavage sites. Findings that cleavage-re-
sistant forms of proTGFa activate EGF receptor in
coculture models (Brachmann et al., 1989; Wong et al.,
1989) have been extended by subsequent observations
that intact precursors to other EGF family members
are also bioactive (Mroczkowski et al., 1989; Dobashi
and Stearn, 1991). This raises unanswered questions as
to the relative importance of membrane-tethered ver-
sus soluble EGF family growth factors in various in
vivo contexts.
Release of the fully processed 50-amino acid TGFa
peptide (Marquardt et al., 1983) from proTGFa de-
pends on cleavage of alanine-valine bonds at the
amino and carboxyl termini, with both cleavage sites
flanked by additional small apolar amino acids (ala-
nine, valine, or leucine). The similarity of these pro-
TGFa processing sites to those typically cleaved by
elastase enzymes has been previously noted, and ex-
ogenous elastases will cleave larger proTGFa deriva-
tives to a species that comigrates with the 50-amino
acid protein (Ignotz et al., 1986; Luetteke et al., 1988;
Mueller et al., 1990). However, studies comparing the
effects of various protease inhibitors on proTGFa pro-
cessing suggest that elastase-like enzymes may not be
responsible for these events in situ (Pandiella et al.,
1992). Moreover, despite the apparent similarity of the
two cleavage sites, distinct enzymes could be in-
volved. Hence, while the amino-terminal cleavage oc-
curs at a much faster rate in transfected CHO cells
(Teixido et al., 1990), biological fluids and medium
conditioned by tumor cell lines contain larger soluble
TGFa proteins that are apparently derived by cleav-
age of the carboxyl-terminal cleavage site only (Ignotz
et al., 1986; Bringman et al., 1987; Luetteke et al., 1988).
More recently, attention has focused on the activa-
tion of TGFa secretion by diverse treatments including
exposure to serum factors, calcium ionophores, and
particularly phorbol esters (phorbol 12-myristate 13-
acetate [PMA]; Pandiella and Massague, 1991a,b; Pan-
diella et al., 1992). Release in response to these agents
occurs rapidly (i.e., within minutes) and is attributable
to proteolysis of cell surface proTGFa (Bosenberg et
al., 1993). The phenomenon of activated cleavage is not
restricted to proTGFa, and the ectodomains of other
cell surface proteins, including KL, are also rapidly
shed (Stein and Rettenmier, 1991; Huang et al., 1992).
Nevertheless, activated processing of proTGFa and
KL demonstrate different, albeit overlapping, sensitiv-
ities to different protease inhibitors (Pandiella et al.,
1992). Most surprisingly, PMA-induced cleavage was
found to be dependent on the presence of a valine
residue located at the carboxyl terminus of the cyto-
plasmic domain of proTGFa (Bosenberg et al., 1992).
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Additionally, a chimeric precursor containing the
ectodomain of proTGFa and the cytoplasmic region of
KL (which also includes a carboxyl-terminal valine)
also undergoes activated cleavage (Bosenberg et al.,
1992). This indicated that the cytoplasmic sequences of
proTGFa could be replaced by the equivalent domain
from another integral membrane growth factor that
similarly undergoes activated cleavage. These find-
ings were interpreted to suggest a novel proteolytic
cleavage activity that acts on proTGFa sequences in
the extracellular environment but is regulated by in-
tracellular signals involving the proTGFa carboxyl-
terminal valine. As a result, attention has focused on
the PMA-induced proteolytic activity, even though
the relationship of this activity to constitutive pro-
TGFa processing has not been firmly established.
In this report, we reexamine the role of cytoplasmic
determinants and, particularly, the carboxyl-terminal
valine residues in proTGFa maturation and process-
ing. In so doing, we have used ras-transformed rat
liver epithelial cells as a model system because these
cells actively express and process proTGFa encoded
by the endogenous gene. Our results indicate that the
carboxyl-terminal valines are predominantly required
for precursor routing and maturation and that the
cytoplasmic domain is otherwise not required for con-
stitutive secretion.
MATERIALS AND METHODS
Cell Lines and Materials
RI cells (kindly provided by S. Strom, University of Pittsburgh)
were grown in Eagle's minimal essential medium containing 10%
fetal bovine serum and 50 ,ug/ml gentamicin. Chinese hamster
ovary (CHO) cells (American Type Culture Collection, Rockville,
MD) were cultured in DMEM with 10% fetal bovine serum, 0.1 mM
nonessential amino acids, and 50 ,ug/ml gentamicin. All media and
supplements were from Life Technologies (Grand Island, NY) un-
less otherwise noted. Mouse monoclonal antibodies against the
hemagglutinin (HA) epitope were from Berkeley Antibody (Rich-
mond, CA; clone 16B12) or from Boehringer Mannheim (Indianap-
olis, IN; clone 12CA5). Antibody directed against the FLAG epitope
(M2) was obtained from Eastman Kodak (New Haven, CT). Rabbit
anti-GRP78 (BiP) polyclonal antiserum was obtained from Affinity
Bioreagents (Neshanic Station, NJ). Rhodamine-conjugated donkey
anti-mouse and fluorescein-conjugated donkey anti-rabbit IgGs
were obtained from Chemicon International (Temecula, CA), and
peroxidase-conjugated goat anti-mouse IgGl and IgG2b were from
Boehringer Mannheim. The vectors pCEP4 and pcDNA3 were ob-
tained from Invitrogen (San Diego, CA). Oligonucleotide primers
were synthesized by the University of North Carolina Nucleic Acids
Core Facility.
Mutant Construction and Cell Transfection
PCR-based site-directed mutagenesis was used to insert the HA
(YPYDVPDYA) and FLAG (DYKDDDDK) epitopes and to create
the AV mutant. The oligonucleotide primer prHA was used to
introduce the HA epitope in proTGFa, primers prFLAGAV and
prAV were used to produce FLAG-tagged wild-type (Wt) and AV
variants, and primer prAV was used to generate AVHA. The se-







These primers were used in mutagenic reactions with Vent DNA
polymerase (New England Biolabs, Beverly, MA) and a 540-bp
TGFa cDNA in pBluescript (Stratagene, La Jolla, CA). The first PCR
used vector T7 sequencing primer and mutagenic primer; purified
product was then used as the forward primer in the second PCR
with the reverse vector T3 primer. Resulting products were purified,
digested with EcoRI, and subcloned into modified pCEP4 (R1) or
pcDNA3 (CHO) vectors. The authenticity of cloned sequences was
confirmed by the University of North Carolina Automated DNA
Sequencing Facility.
The two cytoplasmic truncation mutants (T129C/V) were pro-
duced by using the Muta-Gene Phagemid In Vitro Mutagenesis
Version 2 Protocol (Bio-Rad, Richmond, CA). Briefly, epitope-
tagged proTGFa construct was introduced into Escherichia coli strain
CJ236 for production of single-stranded uracil-containing template.
The single-stranded DNA was annealed to two phosphorylated
oligonucleotide primers that were designed to produce constructs
encoding truncated proTGFa proteins terminating with either a
natural cysteine at position 129 (prT129C) or, alternatively, a valine




Annealing reactions also included a primer designed to eliminate
a novel diagnostic BstBI restriction endonuclease site present in
parental vector sequence. Synthesis reactions were then performed,
and the resulting products were transfected into BMH cells for
inactivation of the uracil-containing DNA. Plasmid DNAs isolated
from the BMH cells were digested with BstBI to eliminate DNA
lacking the desired mutation, and the digestion products were
transfected into bacterial strain DH5a for the final amplification.
The resulting truncated proTGFa coding sequences were confirmed
as described above and subcloned into the eukaryotic expression
vector pCEP4. This vector, which carries a hygromycin B-selectable
marker, was modified by removal of the Epstein-Barr virus origin of
replication and nuclear antigen. For CHO cell transfections, con-
structs were also cloned into pcDNA3.
Expression vectors were introduced into Rl and CHO cells by
calcium phosphate transfection or with Lipofectamine (GIBCO/
BRL). Multiple geneticin-(CHO) or hygromycin B-(Rl) resistant
clones were isolated, and those expressing appropriate levels of
vector-encoded transcript were identified by Northern blot analysis
of total RNA (Berkowitz et al., 1996).
Cell Lysate Analyses
For Western blot analysis, near-confluent monolayers were dis-
solved in lysis buffer [1% Triton X-100, 25 mM Tris, pH 7.4, 300 mM
NaCl, 1 mM CaCl2, 1 mg/ml phenylmethylsulfonyl fluoride
(PMSF), 18 ,tg/ml aprotinin, 10 ,ug/ml leupeptin] and placed on ice
for 30 min. Clarified lysates were incubated with anti-HA or anti-
FLAG (3 ,ug/500 gg of lysate protein) for a minimum of 4 h at 4'C,
and tagged TGFa-antibody complexes were incubated for 1 h after
the addition of protein G-agarose (Life Technologies, Grand Island,
NY) that had been washed once in ice-cold lysis buffer. Pelleted
complexes were washed four times with ice-cold lysis buffer, resus-
pended in sample buffer [62.5 mM Tris-Cl, pH 6.8, 2% SDS, 10%
glycerol, 5% 3-mercaptoethanol (13-ME), 0.25% phenol red], and
boiled for 5 min before loading on 15% polyacrylamide gels. After
electrophoresis, gels were soaked for 10 min in 1 x Tris-glycine (25
mM Tris base, 192 mM glycine, pH 8.3), and proteins were trans-
ferred to prewetted Immobilon-P membrane (Millipore, Bedford,
MA). Blots were blocked in TBS-T (20 mM Tris base, 140 mM NaCl,
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For pulse-chase analyses, cells were grown to approximately 90%
confluence in complete medium, washed for two 20-min periods
with cysteine-free Eagle's minimal essential medium at 37°C, and
incubated in 0.6 ml of cysteine-free medium containing 200 ,Ci/ml
[35S]cysteine (Amersham International, Arlington Heights, IL) for 20
min at 37°C. The medium was removed, and the cells were washed
in phosphate-buffered saline (PBS) and incubated in complete me-
dium for the indicated chase periods. They were then scraped in
lysis buffer and incubated on ice for 30 min. After clarification by
centrifugation, TGFa proteins were immunoprecipitated (with anti-
FLAG or anti-HA) and resolved on 15% polyacrylamide gels. Gels
were fixed in 25% isopropanol and 10% acetic acid for 30 min,
soaked in Amplify for 30 min (Amersham International), dried, and












Figure 1. (A) Diagram of dual-tagged proTGFa proteins. Wt de-
notes the Wt proTGFa sequence, and AV is a mutant lacking the two
carboxyl-terminal valine residues. The positions of the inserted HA
and FLAG epitopes are indicated. The solid box marks the fully
processed 50-amino acid TGFa sequence, the shaded box denotes
the signal peptide, and the adjacent single site of N-linked glyco-
sylation is indicated by the branching symbol. Arrows mark the
positions where proteolytic cleavage must occur to release the ma-
ture 50-amino acid TGFa. (B) As in A, except that the indicated
proTGFa proteins are tagged only with the HA epitope. WtHA, Wt
proTGFa; ZVHA, a mutant lacking the two carboxyl-terminal va-
lines; T129C, a truncation mutant lacking most of the cytoplasmic
domain and terminating with a natural cysteine residue; T129V, an
alternate truncation mutant terminating with a valine residue in
place of the cysteine.
pH 7.6, 0.05% Tween 20) containing 5% nonfat dry milk for .2 h,
rinsed in lx TBS-T for 10 min, and incubated with primary anti-
body for 60 min. Blots were washed for four 10-min periods in
TBS-T, and then incubated with secondary antibody for an addi-
tional 60 min. Peroxidase-conjugated goat anti-mouse IgGl and
IgG2b secondary antibodies (diluted to 1:10,000) were used to detect
anti-FLAG and anti-HA, respectively. Blots were incubated in Su-
perSignal Substrate (Pierce, Rockford, IL) for 5 min before exposing
them to x-ray film to detect chemiluminescence.
Immunofluorescence
Cells were grown to approximately 70% confluence on coverslips,
rinsed three times with solution A (PBS, 0.5% bovine serum albu-
min) at 4°C, and then incubated for 60 min at 4°C in a 1:40 dilution
of anti-HA in solution A. Cells were rinsed as before, fixed for 10
min in 3.7% paraformaldehyde in PBS, rinsed again, and incubated
for 60 min at room temperature (RT) in a 1:40 dilution of rhoda-
mine-conjugated donkey anti-mouse antibody in solution A. Cov-
erslips were then rinsed three times in solution A, once in H20, and
mounted. For cytoplasmic staining, cells were rinsed, fixed as
above, permeabilized in 0.5% Triton X-100 for 10 min, and incubated
for 60 min at RT in solution A containing a 1:40 dilution of anti-
FLAG. Coverslips were rinsed and the rhodamine-conjugated sec-
ondary antibody applied as above. The procedure for anti-BiP stain-
ing was identical except that cells were incubated with primary
antibody for 2 h, and the primary antibody was visualized with a
1:40 dilution of fluorescein isothiocyanate-conjugated donkey anti-
rabbit in solution A.
Glycosidase Treatments
After immunoprecipitation of protein-antibody complexes with
protein G-agarose, pellets were resuspended in 40 ,ul of endoglyco-
sidase H buffer (3.6 mM Na2HPO4/NaH2PO4 [pH 5.51, 0.05% SDS,
4 jig/ml PMSF, 70 mM X3-ME) and boiled for 5 min. After centrif-
ugation at 12,000 rpm for 20 s, supernatant was collected and
incubated with 4 mU of endoglycosidase H for 4 h at 37°C. After the
addition of 44 ,ul of 2x sample buffer (0.125 M Tris-Cl, pH 6.8, 4%
SDS, 20% glycerol, 10% ,3-ME), samples were boiled for 5 min and
resolved by SDS-PAGE. For neuraminidase treatment, immunopre-
cipitates were resuspended in 40 ,ul of 50 mM sodium acetate (pH
5.2), incubated with 40 mU of neuraminidase (sialidase, Boehringer
Mannheim) for 30 min at 37°C, and processed as described above.
Medium Analyses
For medium conditioning, cells were grown to approximately 75%
confluence in 150-mm dishes, rinsed in serum-free medium for two
20-min periods at 37°C, and placed in serum-free medium for the
indicated time periods. Conditioned medium was clarified and
treated with 1 mM PMSF, and medium proteins were concentrated
by using Sep-Pak Plus C18 cartridges (Waters, Milford, MA) as
previously described (Sandgren et al., 1990). Resulting samples were
normalized relative to the amount of lysate protein prior to analysis.
For ELISAs, HA peptide or Sep-Pak-enriched samples were incu-
bated in 96-well radioimmunoassay plates ovemight at RT (Costar,
Cambridge, MA). Each well was rinsed three times with wash
solution (100 mM NaCl, 50 mM Tris-Cl, pH 7.4, 0.05% Tween 20),
and blocking solution (0.25% bovine albumin, 100mM NaCl, 50 mM
Tris-Cl, pH 7.4, 1 mM EDTA, pH 7.5, 0.05% Tween 20) was added
for 60 min at RT. Cells were rinsed three times with wash buffer and
incubated with a 1:1000 dilution of mouse anti-HA antibody in
blocking buffer for 60 min at RT. Cells were washed four times and
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incubated with a 1:1000 dilution of alkaline phosphatase-conjugated
secondary antibody in blocking buffer for 60 min at RT. Wells were
washed four times, and p-nitrophenyl phosphate (Sigma 104 phos-
phate substrate) was added. After 60 min at RT, plates were read on
a DuPont Vmax kinetic microplate reader. Sep-Pak-enriched medium
proteins were also analyzed by Western blot as described above.
RESULTS
Construction of Epitope-tagged TGFa Precursors
Typically, studies of proTGFa processing have been
performed with transfected cells that do not express
the endogenous TGFa gene (e.g., CHO cells). We
wished instead to examine processing of Wt and mu-
tant proTGFa proteins in cells that normally produce
and secrete this growth factor. We chose a ras-trans-
formed rat liver epithelial cell (RLEC) line, Rl, because
it contains relatively high levels of TGFa mRNA
(Berkowitz et al., 1996) and actively secretes TGFa into
the medium. Additionally, EGF receptor (EGFR) is
undetectable in this cell line. The latter point has prac-
tical importance because we wished to monitor TGFa
secretion partly by measuring its accumulation in the
medium. An unpublished comparison of related
RLEC clones that express equivalent levels of TGFa
mRNA revealed an inverse correlation between the
amount of EGFR protein detected by Western blot and
the level of TGFa in conditioned medium. This sug-
gested that TGFa is rapidly internalized when EGFR is
present at significant levels.
To distinguish TGFa species expressed from exoge-
nous vectors (versus those produced from the endog-
enous gene), we tagged the transfected proTGFa with
two distinct epitopes (Figure 1A). The influenza HA
epitope was incorporated between amino acids 42 and
43, which correspond to positions 4 (His) and 5 (Phe)
of the fully processed 50-amino acid TGFa. This re-
gion of the mature growth factor is relatively unim-
portant for biological activity (Defeo-Jones et al., 1988),
and it was recently tagged by others (Arribas and
Massague, 1995). The FLAG epitope, on the other
hand, was incorporated between amino acids 157 and
158 (of 159-amino acid proTGFa), immediately pre-
ceding the two terminal valine residues of the Wt
proTGFa cytoplasmic domain. We chose to retain the
two terminal valine residues in their normal position
because a prior study indicated that they were essen-
tial for activated cleavage of proTGFa (Bosenberg et
al., 1992). However, to test this thesis with Rl cells, we
also created a variant of the dual-tagged TGFa pre-
cursor (AV) that lacked the two terminal valines and
hence contained the FLAG sequence at its carboxyl
terminus (Figure 1A). The two proTGFa variants were
cloned into the mammalian expression vector pCEP4
under the control of the cytomegalovirus promoter,
and the resulting vectors were transfected into Rl
cells. Stable transformants expressing comparable lev-
els of the two novel TGFa transcripts (WtIOw and AV)
A B ; o*

























Figure 2. Expression and localization of dual-tagged proTGFa
constructs. (A) Northern blot analysis. RI cells were stably trans-
fected with either parental pCEP4 vector (Mock) or pCEP4 con-
taining epitope-tagged Wt or mutant (AV) proTGFa sequences.
Total RNA was prepared from selected clones and examined by
Northern blot analysis for expression of vector-encoded tran-
scripts. The probe was the coding portion of mouse TGFa cDNA.
Wthigh cells expressed severalfold higher levels of the appropri-
ately sized transcript that WtlOw cells. (B) Western blot analysis.
Total cell lysates were immunoprecipitated with anti-FLAG, and
the proteins resolved by SDS-PAGE, transferred to blots, and
probed with anti-HA (left) or anti-FLAG (right). The positions of
molecular weight markers are shown on the left, and the appar-
ent sizes of tagged proTGFa species are shown on the right. An
asterisk denotes an apparently specific but variably detected
band of approximately 44 kDa. (C) Pulse-chase experiment. Cell
clones expressing the indicated proTGFa proteins were incu-
bated in cysteine-free medium supplemented with [35S]cysteine
for 20 min at 37°C and then transferred to complete medium
without labeled cysteine for the indicated times. Cells were lysed,
proteins were immunoprecipitated with anti-FLAG, and recov-
ered proteins were analyzed by SDS-PAGE/autoradiography.
The apparent molecular weights of prominent bands are shown
on the left, and an asterisk marks a minor variably observed
band. Below, a section of an overexposed autoradiogram more
clearly reveals the presence of the 16-kDa tail in WtlOw samples.
were then selected (Figure 2A). For comparison, we
also isolated a Wt clone (Wthigh) that expressed the
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transfected vector at levels severalfold higher than
those of Wt1Ow (Figure 2A), and we established a line
(Mock) that was stably transfected with the parental
(non-TGFa-encoding) vector. All clones used in this
study expressed the novel TGFa transcripts at levels
that were significantly higher than those of the endog-
enous mRNA.
Carboxyl-Terininal Valines of ProTGFac Are
Required for Efficient Cell Surface Localization in
Rl Cells
To examine expression of Wt proTGFa, we immuno-
precipitated cell lysates with the FLAG antibody and
then performed Western blot analyses using either
anti-HA (Figure 2B, left) or anti-FLAG (Figure 2B,
right). Anti-HA identified a prominent protein of ap-
proximately 36 kDa present in both WtlOw and Wthigh
cells but also detected a second major protein of 25
kDa in Wthigh samples. Anti-FLAG, on the other hand,
identified a prominent product of 16 kDa in both
Wt1Ow and W high cells but also recognized additional
species of 25 and 36 kDa in the Wthigh lysates. (Note
that in some experiments, anti-FLAG also detected
low levels of the 36-kDa product in Wtlw samples;
however, the 16-kDa polypeptide was always pre-
dominant.) By taking into account the positions of the
HA and FLAG epitopes and past studies of proTGFa
processing (Bringman et al., 1987; Gentry et al., 1987;
Teixido et al., 1990), these data suggest that the 25-kDa
protein is an initial translation product, and the 36-
kDa protein corresponds to a more extensively glyco-
sylated form. Because the 16-kDa protein includes the
carboxyl-terminal FLAG epitope but not the HA tag, it
presumably corresponds to a proteolytic "tail" prod-
uct that contains only the juxtamembrane, transmem-
brane, and cytoplasmic sequences. These conclusions
were corroborated by pulse-chase experiments in
which 35S-labeled lysate proteins were immunopre-
cipitated with anti-FLAG. Analysis of Wt'Ow cells
clearly established a temporal sequence in which the
initial 25-kDa protein was converted to the 36-kDa
product, and the latter then to the 16-kDa tail (Figure
2C, left; note that an overexposure of the Wtl'w tail is
shown below). This temporal sequence, which was
confirmed with Wthigh cells, is consistent with previ-
ous descriptions of proTGFa processing. The relative
accumulation of the 25-kDa protein in Wthigh versus
Wt1Ow cells indicates that maturation to the 36-kDa
product was rate-limiting when proTGFa was ex-
pressed at particularly high levels.
We similarly examined proTGFa expression in the
AV clone of Rl cells by anti-FLAG immunoprecipita-
tion followed by anti-HA or anti-FLAG Western blot
analysis. Because this clone expressed vector-derived
RNA at a level that was comparable to that of Wtlow
cells, we expected a similar profile of epitope-tagged
proteins. In fact, the pattern was quite different. Thus,
anti-HA identified a prominent 25-kDa product, with
only minor amounts of the 36-kDa protein detected
(Figure 2B, left). Anti-FLAG also predominantly iden-
tified the 25-kDa protein, with only minor amounts of
the 16-kDa tail detected after long exposures (Figure
2B, right). These results suggested that the 25-kDa
product was accumulating in AV cells, with greatly
reduced maturation to the 36-kDa species. This inter-
pretation was supported by pulse-chase analyses,
which clearly showed that the initial 25-kDa protein
turned over with little or no conversion to the 36- or
16-kDa products (Figure 2C, right).
To confirm impaired surface localization of the AV
mutant, we performed immunofluorescent staining of
intact cells. The use of anti-HA yielded marked sur-
face staining of WtlOw cells (Figure 3c). In contrast, the
surface staining of AV (Figure 3b) cells was only
barely increased relative to that of the mock-trans-
fected control cells. Anti-FLAG staining of fixed WtlOw
cells yielded a conspicuous punctate staining pattern
in the cytoplasm (Figure 3d), consistent with vesicular
transport of proTGFa to the cell surface. In contrast,
anti-FLAG staining of permeabilized AV cells was
largely restricted to a perinuclear structure (Figure 3e).
An antibody directed against an established endoplas-
mic reticulum (ER) marker protein, BiP/GRP78 (Col-
lier et al., 1993; Green et al., 1995), produced similar
staining of permeabilized AV cells (Figure 3f), whereas
staining with a Golgi-specific marker yielded a dis-
tinct pattern. These results corroborated the preceding
findings and indicated that the AV protein (i.e., the
predominant 25-kDa form) accumulated in the rough
endoplasmic reticulum (RER).
We also examined the effects of specific deglycosi-
dases on TGFa species present in cell lysates. En-
doglycosidase H (Figure 4, lanes E), which is not ac-
tive against the complex carbohydrate of mature
glycoproteins, did not affect the mobility of the 36-kDa
protein from WtlOw cells, but it reduced the apparent
size of the 25-kDa product in the same lysate by ap-
proximately 5 kDa. In contrast, neuraminidase, which
removes the terminal sialic acid residues of mature
glycoproteins, reduced the size of the 36-kDa protein
by approximately 3 kDa without affecting the 25-kDa
product (Figure 4, lanes N). Similar results were ob-
tained with AV samples (Figure 4, right), except that
only minor amounts of the 36-kDa form were present
as expected. Collectively, these various data confirm
that the 25-kDa protein is an ER form, whereas the
36-kDa protein has exited this compartment and likely
accounts for the surface immunostaining.
Thus, these various results reveal a correlation
among extensive glycosylation of proTGFa, its move-
ment from the RER to the cell surface, and its apparent
proteolytic processing. They are supported and ex-
tended by studies of TGFa secretion described later.
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Figure 3. (a-c) Cell surface staining of tagged proTGFa proteins. Intact cells from the indicated clones were incubated with anti-HA for 60
min at 4°C, fixed for 10 min in paraformaldehyde, and incubated with rhodamine-conjugated anti-mouse IgG for 1 h at RT. (d-f) Cytoplasmic
staining of tagged proTGFa proteins. The indicated cells were fixed as above, permeabilized, and incubated with either anti-FLAG or anti-BiP
for 1 or 2 h, respectively. Primary antibody was then visualized with fluorescein isothiocyanate-conjugated anti-rabbit.
Similar Results Are Obtained with CHO Cell Clones
and with Non-FLAG-tagged ProTGFa
Since a previous study found that (nontagged) AV-like
proTGFa mutants were normally expressed on the
surface of CHO cells (Bosenberg et al., 1992), we per-
formed the following experiments. First, we con-
firmed that routing of the AV mutant was also im-
paired in CHO cells. CHO cell clones stably
transfected with epitope-tagged Wt and AV constructs
were selected, and the expression of TGFa species in
these cells was then compared. Pulse-chase analysis
of a CHO Wt clone revealed a temporal pattern of
proTGFa maturation and processing that was similar
to the Rl Wt pattern, except that minor products of 22
and 23 kDa were also detected (Figure 5A, top). In
marked contrast, examination of a CHO AV clone
showed that the initial 25-kDa species largely turned
over with little evidence of subsequent maturation or
processing (Figure 5A, bottom). These results were
confirmed by Western blot analysis. Anti-HA (Figure
5B, left) and anti-FLAG (Figure 5B, right) detected
predominant 36-kDa surface and 16-kDa tail forms,
respectively, in the CHO Wt clone, but the 25-kDa
ER-localized protein was the major form recognized
by both antibodies in CHO AV samples. Moreover,
anti-HA immunostaining of intact CHO clones re-
vealed a marked decrease in surface staining of CHO
cells expressing the AV mutant compared with those
expressing the Wt protein. Thus, removal of the car-
boxyl-terminal valines of proTGFa had similar conse-
quences in RI and CHO cells.
Second, to exclude the possibility that our results
were influenced by placement of the FLAG epitope
immediately preceding the carboxyl-terminal valines,
we made new Wt and AV constructs (WtHA and
AVHA) that were tagged only with the HA epitope
(Figure 1B). Pulse-chase analysis of an RI clone ex-
pressing WtHA showed the expected conversion of a
24-kDa species to a modified protein of 35 kDa (these
products are slightly smaller than those of the double-
tagged precursor due to the absence of the FLAG
epitope; Figure 6A, top). Because these constructs
were tagged only with the HA epitope, we could not
monitor the appearance of the proTGFa tail. Never-
theless, pulse-chase analysis of an Rl AVHA clone
clearly revealed that in the absence of the carboxyl-
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Figure 4. Effect of glycosidases on tagged proTGFa proteins. Anti-
FLAG immunoprecipitates from the indicated lysates were resus-
pended in the appropriate buffers and incubated either with en-
doglycosidase H (E) or neuraminidase (N) at 37°C for 4 h or 30 min,
respectively. Samples were then analyzed by SDS-PAGE. The ap-
parent molecular weights of prominent species are shown on the
left. The star marks a band also generated when samples were
incubated in neuraminidase buffer lacking enzyme. The asterisk
denotes a nonspecific band.
terminal valines, the initial 24-kDa protein turned over
with greatly reduced conversion to the 35-kDa surface
form (Figure 6A, bottom). Western blots of anti-HA-
immunoprecipitated cell lysates confirmed that al-
though the 35-kDa surface form was the predominant
species detected by anti-HA in samples from WtHA
cells (Figure 6B, left), the 24-kDa product was the
primary form recognized in AVHA samples (Figure 6B,
right). (Note that as was the case with the dual-tagged
AXV mutant, minor amounts of the larger surface form
were detected when samples were overloaded, sug-
gesting that although maturation of the AV mutants
was dramatically impaired, it was not completely
blocked.) Finally, anti-HA surface staining of AVHA
cells was consistently reduced compared with that of
WtHA cells. These various results, which are consistent
with studies of TGFa secretion described below, cor-
roborate those obtained with the dual-tagged pro-
TGFa proteins and confirm that carboxyl-terminal va-
line residues of proTGFa have a critical role in
precursor maturation and routing.
TGFa Is Constitutively Secreted by Clones
Expressing Wt but Not AV Forms of ProTGFao
To measure constitutive secretion of TGFa species by
Wt and AV clones, we used an HA-specific ELISA.
Serum-free medium conditioned for 24 h by Wt1Ow or
WtHA cells contained significant amounts of ELISA
activity relative to the subtracted background activity
of medium from control (Mock) cells. Comparison
with an HA peptide standard indicated that soluble
TGFa levels ranged from 5 to 10 ng/ml in medium
conditioned by cells expressing Wt precursor, consis-
















Figure 5. Expression of Wt and mutant (AV) proTGFa proteins
expressed in CHO cells. (A) Pulse-chase analysis. (B) Western blot
analysis. Experiments were performed as described in Figure 2.
Asterisks denote nonspecific bands.
ure 7). In contrast, medium conditioned by cells ex-
pressing the AV or AVHA constructs contained
markedly reduced activity (<1 ng/ml TGFa) that was
only minimally increased relative to background.
Consistent with the ELISA results, Western blot
analysis using anti-HA revealed that a prominent HA-
tagged species of approximately 26 kDa was present
in medium conditioned by WtlOw and WtHA clones but
not by AV or AVHA cells (Figure 8A). Further charac-
terization of the secreted 26-kDa protein revealed that
it was not recognized by anti-FLAG and was thus
distinguished from the 25-kDa lysate protein that con-
tains the FLAG epitope and cytoplasmic sequences
(see Figure 2B). Additionally, it was quantitatively
converted to a much smaller HA-tagged protein by
pancreatic elastase, and it contained N-linked carbo-
hydrate since its apparent molecular weight was re-
duced by several kilodaltons after treatment with N-
glycanase (Figure 8B). These data indicate that the
26-kDa protein corresponds to ectodomain sequences
of proTGFa and includes the 50-amino acid TGFa
polypeptide together with amino-terminal precursor
sequences containing the single N-glycosylation site. It
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is presumably generated by selective proteolytic
cleavage of the precursor's carboxyl-terminal Ala-Val
(or adjacent) bond. Thus, the ELISA and Western blot
assays extend and corroborate the protein and immu-
nofluorescence analyses described above.
Addition of a Carboxyl-Terminal Valine Enhances
Maturation of a Truncated ProTGFxv Lacking Most
of the Cytoplasmic Domain
We constructed two variants of a truncated proTGFa
that lacked most of the cytoplasmic domain: T129C
terminated with a natural cysteine residue at position
129, and T129V replaced Cys129 with a carboxyl-ter-
minal valine (Figure 1B). Both variants were tagged
with the HA epitope as described for full-length pro-
TGFa and introduced into Rl cells. Lysates from
T129C and T129V clones were immunoprecipitated
with anti-HA and then examined by Western blot
analysis using the same antibody. Figure 9A shows
that the predominant protein identified in both T129V
and T129C samples was a 19-kDa species that was
predicted, on the basis of size, to correspond to the
initial translation product. However, both samples
also contained an additional anti-HA-recognized spe-
cies of approximately 28 kDa; this latter protein pre-
sumably corresponds to the fully glycosylated trun-
cated proTGFa. The observation that this 28-kDa
protein was present at significantly higher levels in
T129V versus T129 cells suggests that the addition of a
carboxyl-terminal valine also enhanced the matura-
tion of the proTGFa truncation mutant. This interpre-
tation is consistent with the finding that T129V cells
showed enhanced anti-HA surface immunostaining
compared with T129C cells (Figure 9B) and also se-
creted higher levels of TGFa into the medium. Thus,
the TGFa-specific ELISA activity of T129V medium
was roughly threefold higher than that of T129C cells
and in fact approached that of cells expressing the Wt
proTGFa counterpart (WtHA) (Figure 7). In agreement,
Western blot analyses showed that the secreted 26-
kDa protein was present at significantly higher levels
in T129V medium compared with T129C samples (Fig-
ure 8A).
Collectively, the results of the above described
Western blot, surface immunofluorescence, and me-
dium analyses indicate that the valine requirement
was recapitulated even when the cytoplasmic se-
quence of proTGFa had been largely deleted. This, in
turn, suggests that the role of the carboxyl-terminal
valine in full-length proTGFa maturation is unrelated
to correct folding of the cytoplasmic domain of the
precursor.
DISCUSSION
Our results show that carboxyl-terminal valine resi-










Figure 6. Expression of Wt and mutant (AV) proTGFa proteins
tagged only with the HA epitope. (A) Pulse-chase analysis. (B)
Western blot analysis. Experiments were performed as described in
Figure 2, except that immunoprecipitations were performed with
anti-HA. Note that lanes 2 and 4 of the Western blot include dual-
tagged WtW'O and AV samples for comparison. The apparent mo-
lecular weights of the dual-tagged proteins are shown on the left,
and those of the HA-tagged proteins are shown on the right. The
asterisk marks a nonspecific band.
ation and routing to the cell surface. Specifically, pro-
TGFa mutants lacking the terminal valines were
substantially reduced in size, consistent with incom-
plete glycosylation, and they remained sensitive to
endoglycosidase H. This enzyme removes asparagine-
linked carbohydrate chains from polypeptides in the
RER but has no effect on the processed oligosaccha-
rides of proteins that have been transferred to the
Golgi (Kornfeld and Kornfeld, 1985). The resulting
suggestion that these proTGFa mutants accumulate in
the RER was corroborated by localization studies,
which showed them to be present at substantially
reduced levels on the cell surface and instead to colo-
calize with an RER marker. Finally, consistent with
these findings and evidence that cleavage of proTGFa
occurs at the cell surface (Bosenberg et al., 1993), cells
expressing these mutants secreted dramatically lower
levels of soluble TGFa species. The finding that the AV
form of proTGFa is present at markedly reduced lev-
els on the cell surface contradicts a previous report
that proTGFa mutants lacking the carboxyl-terminal
valines were localized normally to the surface of CHO
cells but not subject to phorbol ester-induced proteo-
lytic processing (Bosenberg et al., 1992). However, we
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Figure 7. ELISA measurements of TGFa secretion. Cells from the
indicated clones were grown to approximately 75% confluency,
switched to serum-free medium, and incubated at 37°C for an
additional 24 h. The resulting conditioned medium was clarified
and concentrated by chromatography on Sep-Pak Plus C18 car-
tridges. Equivalent protein samples were then analyzed by using an
HA-specific ELISA as described in MATERIALS AND METHODS.
Medium TGFa concentrations were estimated by comparisons with
a standard curve generated with an HA peptide standard.
reproduced our results in CHO cells and with both
full-length and truncated proTGFa molecules that
lacked the cytoplasmic FLAG tag. In light of these
results, it seems possible that the reported reconstitu-
tion of phorbol ester-induced processing of a pro-
TGFa/KL chimera whose cytoplasmic domain (in-
cluding a carboxyl-terminal valine) corresponded to
that of KL (Bosenberg et al., 1992) could instead be
accounted for by reconstituted transport of the chi-
meric protein from the RER to the cell surface.
The aforementioned findings are consistent with lit-
erature reports of mutations affecting the intracellular
trafficking (i.e., maturation) of a variety of secreted or
integral membrane proteins. For example, human a-
1-proteinase inhibitor (AlPi) deficiency disease results
from frameshift mutations that yield abnormal carbox-
yl-terminal sequence and premature terminations.
Studies of similar deliberately produced mutations in
transfected cells revealed that a nearly full-length pro-
tein containing at least 391 of 394 amino acids was
required for movement of newly synthesized AlPi
from the RER to the Golgi (Brodbeck and Brown,
1992). Comparison of nested AlPi mutants revealed
an especially critical role for a proline residue located
four amino acids upstream from the carboxyl termi-
nus of the full-length protein. Similarly, variable spon-
taneous deletions of the carboxyl-terminal 22 amino
acids of thyroxine-binding globulin caused that nas-
cent protein to be retained in the RER with resultant
lack of secretion (Miura et al., 1994). Illustrating that
even relatively subtle mutations can have comparable
effect, P-glycoprotein mutants bearing individual sub-
stitutions of several glycine residues in the cytoplas-
mic domain had reduced mass (presumably due to
incomplete glycosylation), were endoglycosidase H
sensitive, and failed to confer normal multidrug resis-
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Figure 8. Western blot analyses of soluble TGFa species. (A) Con-
ditioned medium from the indicated cell clones was collected and
concentrated. Equal amounts of Sep-Pak-concentrated protein from
each sample was then resolved by PAGE, transferred to blots, and
probed with anti-HA. A resulting predominant product of 26 kDa is
marked. Lanes 1 and 2 are duplicate samples from separate cultures.
(B) Indicated samples of Wt10' conditioned medium were treated
with 3 jig/ml pancreatic elastase (EL; Elastin Products, Owensville,
MO) for 1 h at RT or 12.5 U/ml N-glycanase (NG; Genzyme,
Cambridge, MA) for 2 h at 37°C prior to blotting with anti-HA. The
apparent molecular weights of resulting species are shown on the
right.
tance when introduced into cells. Collectively, these
results suggest that the P-glycoprotein point mutants
were retained in the RER (Loo and Clarke, 1994).
Likewise, a mutant c-kit (Wn) containing a single point
mutation in the tyrosine kinase domain was reduced
in size and absent from the cell surface. Studies of cells
transfected with Wn cDNA revealed that the mutant
protein was inefficiently glycosylated, endoglycosi-
dase-H-sensitive, and retained in the RER (Koshimizu
et al., 1994). Though the precise mechanisms by which
mutations like these affect protein trafficking is un-
known, incorrect folding of the nascent polypeptide is
a favored hypothesis (Lehrman et al., 1985; Pfeffer and
Rothman, 1987; Lodish, 1988). Alternatively, mutant
proteins may not properly interact with specific trans-
port receptors. In support of the former hypothesis,
mutations of the cytoplasmic domain of influenza vi-
rus HA (Doyle et al., 1986) and single point substitu-
tions distant from the oligosaccharide attachment site
of hepatic al-antitrypsin (Loebermann et al., 1984) that
affect transport from the RER to the Golgi also cause
protein denaturation or misfolding. On the other
hand, the fact that the valine requirement was reca-
pitulated with a proTGFa mutant that lacked virtually
all of the cytoplasmic domain suggests that the effect
of removing the carboxyl-terminal valine is unrelated


















Figure 9. Expression and localization
of proTGFa truncation mutants. (A)
Western blot analysis. Cells expressing
the indicated proTGFa mutants were
lysed and immunoprecipitated with an-
ti-HA. Proteins were resolved by PAGE,
transferred to blots, and probed with an-
ti-HA. (B) Surface immunofluorescence.
Intact cells were probed with anti-HA as
described in Figure 3, a-d.
to cytoplasmic domain foldings. It is interesting to
note in this regard that the carboxyl-terminal valine of
KL was not required for routing of that protein to the
cell surface (Cheng and Flanagan, 1994), even though
its removal inhibited activated processing of a chi-
meric protein containing the proTGFa ectodomain
and KL cytoplasmic sequences (Bosenberg et al., 1992).
These latter results suggest that the valine require-
ment may in part be determined by proTGFa extra-
cellular sequences.
Our finding that the truncation mutant T129V gave
rise to near Wt levels of soluble TGFa suggests that the
cytoplasmic domain of proTGFa is not essential for
constitutive proteolytic processing. This is remini-
scient of the finding that cleavage of KL is also not
dependent on the cytoplasmic domain of that precur-
sor. Of course, we cannot exclude possible quantita-
tive differences in the proteolytic processing of full-
length and truncated proteins. Additionally, we have
not examined whether truncation of the cytoplasmic
domain affects phorbol ester-induced cleavage or de-
termined whether secretion of the truncated protein
occurs through the same pathway. Importantly, our
data also do not exclude possible roles for the cyto-
plasmic domains of proTGFa and KL in other pro-
posed activities such as bidirectional signaling. In this
regard, the KL mutant, S117H, is of particular interest.
The S117H protein contains Wt extracellular and trans-
membrane domains, but its cytoplasmic region is re-
placed with a foreign sequence of similar length (Bran-
nan et al., 1992). Interestingly, this mutant is associated
with severe effects on male germ cell development,
although other cell lineages are also impacted. Al-
though this phenotype could be indicative of a signal-
ing role for the KL cytoplasmic domain, there are
other possible explanations. For example, although
the SL 7H protein is found on the cell surface (Cheng
and Flanagan, 1994), it may be present at reduced
levels compared with Wt KL, perhaps as a result of
inefficient intracellular routing and maturation. If so,
the impairment to RER-Golgi transport could be ex-
aggerated in male germ cells, or this particular cell
type might be more sensitive to the levels of surface or
soluble KL. Finally, a recent study (Shum et al., 1996)
also concluded that proTGFa cytoplasmic sequences
were not required for processing, but surface localiza-
tion and secretion were not directly measured.
Finally, our results also indicate biased recognition
of the juxtamembrane cleavage site of proTGFa. Thus,
medium conditioned by the Rl clones contained a
prominent HA-tagged TGFa of 26 kDa, with little or
no evidence of the fully processed 6-kDa form. Be-
cause this larger species included the mature TGFa
peptide and amino-terminal sequences containing the
N-linked glycosylation site, we presume that proteo-
lytic cleavage was restricted to the carboxyl-terminal
Ala-Val bond in Rl cells (see Figure 1). This contrasts
with reports of rapid cleavage at the amino-terminal
site of proTGFa in transfected CHO cells (Teixido et
al., 1990) but is consistent with the presence of rela-
tively large TGFa species in a variety of cell cultures
and biological fluids. For example, we previously
characterized a 21-kDa TGFa protein that is the prom-
inent TGFa species secreted by the chemically induced
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rat hepatocellular carcinoma line JM1 (Luetteke et al.,
1988). Moreover, soluble TGFa species ranging from
18 to 42 kDa in size have been detected in medium
conditioned by retrovirus-transformed rat cells (Lins-
ley et al., 1985; Teixido et al., 1988), untransformed
bovine anterior pituitary cells (Kobrin et al., 1986), and
even CHO cells (Bringman et al., 1987). The complete
lack of the fully processed 6-kDa form in the present
samples is surprising: perhaps, cleavage at the amino-
terminal site is dampened by the nearby placement of
the HA epitope. Alternatively, processing at this site
could be inhibited by the more extensive glycosylation
of proTGFa that occurs in Rl versus CHO cells. Fi-
nally, cleavage at the amino and carboxyl sites may be
mediated by different proteases (Teixido et al., 1990),
in which case Rl cells could be deficient in the respec-
tive protease. Future experiments will be partly aimed
at distinguishing between these various possibilities.
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